Sr. Leadership

高级领导

• 批准号: 7714404
• 负责人: DONALD L TRUMP
• 金额: $ 13.83万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-28 至 2013-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7714404
• 关键词: Address; Administrator; American Association of Cancer Research; American Society of Clinical Oncology; Appointment; Association of American Cancer Institutes; Awareness; Basic Science; Biology; Cancer Center Support Grant; Caring; Cell Therapy; Cells; Chairperson; Clinic; Clinical; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Consult; Counseling; Coupling; Daily; Decision Making; Development; Education; Faculty; Foundations; Funding; Genes; Growth; Image; Institutes; Institution; Lead; Leadership; Left; Malignant Neoplasms; Marshal; Mayo Clinic Cancer Center; Medicine; Molecular Genetics; Molecular Target; Names; National Comprehensive Cancer Network; Numbers; Ohio; Operative Surgical Procedures; Outpatients; Parents; Participant; Phase Transition; Play; Population; Population Sciences; Positioning Attribute; Process; Program Development; Program Evaluation; Prostate; Recruitment Activity; Research; Research Institute; Research Personnel; Resource Sharing; Resources; Retirement; Role; Roswell Park Cancer Institute; Series; Services; Strategic Planning; Stress; Therapeutic; Time; Universities; Virginia; Vision; Walkers; Work; anticancer research; base; cancer Biomedical Informatics Grid; cancer prevention; drug discovery; experience; health disparity; member; professor; programs; symposium; therapeutic target; trend

SENIOR LEADERSHIP In March 2007 after 10 years of leading RPCI through significant and successful governance restructuring and programmatic expansion efforts, Dr. David Hohn retired as the President and CEO of Roswell Park Cancer Institute (RPCI). Dr. Hohn maintains a part-time position at RPCI as a senior advisor providing counsel to senior leadership on issues relevant to network development, facilities expansion planning and special projects. In addition, after 30 years of service, Dr. Youcef Rustum will be retiring from his role as Associate Director for Core Resources in the first quarter of 2008. In 2005, as Dr, Hohn and the Board of Directors (BOD) of RPCI began planning for a leadership transition, the possibility that Dr. Trump would succeed Dr. David Hohn as President and CEO and CCSG PI was raised. The BOD consulted both with Roswell Park leadership as well as an external panel of advisors. Based on this analysis, the BOD developed a succession plan for Dr. Trump's transition which began January 1, 2006 with his appointment to Associate Director of the Institute. The final phase of the transition occurred, as planned, on April 1, 2007 when Dr. Trump was named President and CEO. It is important to note that Dr. Trump was originally recruited to RPCI in 2002 as the Associate Director for Clinical Research and Co-leader of the Targeted Therapeutics Program at RPCI, positions he maintained until his the transition in 2006. Coupling Dr. Trump's leadership and experience with the detailed planning and execution of this succession plan has allowed for a smooth and effective transition of RPCI leadership. The change in the RPCI Director (Hohn) and two Associate Directors (Trump and Rustum) brought new senior leadership opportunities. With Dr. Trump's transition in 2006 to Associate Director of the Institute, Dr. Alex Adjei was recruited from the Mayo Clinic and appointed to the Associate Director for Clinical Research position. He is also the Chair for the Department of Medicine. Dr. Adjei brings a wealth of scientific and administrative leadership experience in cancer clinical research and will also lead the Molecular Targets and Experimental Therapeutics Program. Similarly, with Dr. Rustum's planned retirement and the departure of Virginia Opipare (Associate Director of Finance and Operations) in 2006, a unique opportunity became available to consolidate the responsibilities of these leadership roles into a single position to provide a more efficient and effective management of Institute operations. In early 2007, Dr. Trump recruited Jeff Walker, MBA from The Ohio State University (OSU) Comprehensive Cancer Center to a new role as the Associate Director for Administration. Mr. Walker brings more than 20 years of experience in leadership in academic/biomedical institutions, spending the last 6 years as the Associate Director for Administration of the OSU Comprehensive Cancer Center. Dr. Rustum will transition his responsibilities to Mr. Walker and remain as a Distinguished Professor and advisor to Dr. Trump and Mr. Walker. Early in 2007 Dr. Trump appointed Dr. Andrei Gudkov as the Associate Director for Basic Research replacing Dr. Michael Brattain who is leaving RPCI June, 2007. Dr. Gudkov, formerly Chairman of the Department of Molecular Genetics at the Lerner Research Institute, Cleveland Clinic Foundation, and a member of the Case Comprehensive Cancer Center, is internationally recognized for his pioneering work in gene and drug discovery. He directs a broad, highly collaborative NCI-funded program combining equally strong basic and translational components. Dr. Gudkov is also the Chair of the Cell Stress Biology Department. The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to the Institute as well as a wealth of scientific program development, and administrative leadership experience garnered from their involvement at other major NCI-designated cancer programs (Case Comprehensive Cancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center, respectively). Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjei serves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees Clinical Research Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, and Dr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. Candace Johnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in the Molecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administrator and oversees the CCSG shared resources. All members of the Senior Leadership Team are active in the faculty recruitment process, serving as chairs or members of search committees. Further they are also involved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating in development activities. Each of these leaders is also active in national cancer research forums and well integrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI [caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regarding important national topics in cancer research, care and education and guaranteeing RPCI awareness of and leadership in the national trends. The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in the primary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, the Executive Council is the major decision-making body of the Institute, responsible for the on-going oversight of the RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadership participates on the CCSG Steering Committee, a committee that meets monthly and includes the research program leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development, Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategic planning, program evaluation, membership review and approval and review of existing and proposed shared resources. Although there are several other venues where the Senior Leadership participates, it is through these two committees that primary decision-making is accomplished. There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006) the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians, increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increase in out patient volume by 42% over this time period. As the number of cancer-focused basic, translational, clinical and population investigators at the RPCI have grown, four new Shared Resources have been established to support the needs of the membership with three more now in development. It is anticipated that the current Senior Leadership team will continue this successful trajectory via developing and executing longterm vision and strategic planning for the Institute.

高级领导 经过10年的带领RPCI经过重大和成功的治理重组，并在2007年3月 程序化扩展工作，戴维·霍恩（David Hohn）博士退休，担任罗斯威尔公园癌（Roswell Park Cancer）的总裁兼首席执行官 研究所（RPCI）。 Hohn博士担任RPCI的兼职职位，担任高级顾问 高级领导与网络开发，设施扩展计划和特殊问题有关的问题 项目。此外，经过30年的服务，Youcef Rustum博士将退休 2008年第一季度核心资源主管。 2005年，随着RPCI的霍恩博士和董事会（BOD）开始计划领导层过渡， 特朗普博士会接替戴维·霍恩（David Hohn）博士担任总裁兼首席执行官，而CCSG PI的可能性可能被提高。 Bod与Roswell Park领导层以及外部顾问咨询。基于此 分析，Bod制定了特朗普博士的过渡计划，该计划于2006年1月1日开始 他任命该研究所副主任。过渡的最后阶段是按计划发生的 2007年4月1日，特朗普博士被任命为总裁兼首席执行官。重要的是要注意，特朗普博士是 最初于2002年招募到RPCI，担任临床研究副主任和 在RPCI的有针对性治疗计划，他一直保持着直到2006年过渡的职位。 特朗普在该继承计划的详细计划和执行方面的领导和经验 允许RPCI领导的平稳有效过渡。 RPCI董事（Hohn）和两名副董事（特朗普和鲁斯特（Trump and Rustum））的变化带来了新的高级高级 领导机会。随着特朗普博士于2006年的过渡到该研究所副主任亚历克斯博士 Adjei是从Mayo诊所招募的，并被任命为临床研究副主任 位置。他还是医学系主任。 Adjei博士带来了大量的科学和 癌症临床研究方面的行政领导经验，还将领导分子靶标和 实验治疗计划。同样，随着Rustum博士的计划退休和离开 弗吉尼亚·欧普帕雷（Virginia Opipare）（金融与运营副总监）于2006年，一个独特的机会变成了 可用于将这些领导角色的责任巩固为一个职位，以提供更多 研究所运营的有效管理。 2007年初，特朗普博士招募了杰夫·沃克（Jeff Walker）， 俄亥俄州立大学（OSU）综合癌症中心的MBA，担任新角色 行政管理主任。沃克先生带来了20多年的领导经验 学术/生物医学机构，在过去6年中担任管理副主任 OSU综合癌症中心。 Rustum博士将把他的职责转换给Walker先生，并留下 作为特朗普博士和沃克先生的杰出教授兼顾问。 2007年初，特朗普博士任命了博士。 安德烈·古德科夫（Andrei Gudkov RPCI，2007年6月。勒纳（Lerner）分子遗传学系主任古德科夫（Gudkov）博士 克利夫兰诊所基金会研究所，案例综合癌症中心的成员是 国际上因其在基因和药物发现方面的开创性工作而受到认可。他指导一个广阔的，高度的 合作NCI资助的计划结合了同样强大的基本和翻译组件。古德科夫博士 也是细胞压力生物学系的主席。 三位新的高级领导人，古德科夫博士，Adjei博士和沃克先生，将新的想法和观点带到 研究所以及丰富的科学计划发展和行政领导经验 从参与其他主要NCI指定的癌症计划（案例综合）中获得 癌症中心，梅奥临床癌症中心和俄亥俄州立大学综合癌症中心 分别）。 每个高级领导者还在CCSG计划或共享资源中扮演着关键的角色。 Adjei博士 充当分子靶标和实验疗法（MTET）的领导者，并监督临床 研究服务，古德科夫博士是细胞压力和生物物理疗法（CSBT）计划的领导者，并且 詹姆斯·马歇尔（James Marshall）博士领导了预防癌症和人口科学（CPPS）计划。 Candace博士 约翰逊是前列腺计划和MTET的积极参与者，而特朗普博士参加 分子靶标和实验治疗计划。沃克先生担任CCSG管理员 并监督CCSG共享资源。高级领导团队的所有成员都活跃于 教师招聘过程，担任搜索委员会的主席或成员。除了他们也是 参与协调EAB会议，年度务虚会，研讨会/研讨会系列和参加 发展活动。这些领导者中的每一个也都在国家癌症研究论坛和井中活跃 纳入这些外部领域的领导和委员会职位（ASCO，AACR，AACI，NCCN，NCI [CABIG，IRGS，家长委员会]）确保他们对 癌症研究，护理和教育方面的重要国家主题，并保证RPCI对和 国家趋势的领导。 高级领导团队每天进行非正式的互动，并每周正式开会 主要行政领导论坛被称为RPCI执行理事会。由特朗普博士主持 执行理事会是该研究所的主要决策机构，负责持续监督 RPCI并解决其成员提出的所有功能问题。此外，高级领导 参加CCSG指导委员会，该委员会每月开会并包括研究 计划负责人以及重要CCSG和研究所计划的领导者[例如，成像发展， 健康差异]。由特朗普博士主持的CCSG指导委员会为战略性 计划，计划评估，会员资格审查和批准以及对现有和拟议共享的审查 资源。尽管高级领导人参加其他几个场所，但它是通过 这两个委员会完成了主要决策。 在上一个融资周期中，RPCI的增长急剧增长。在这个融资周期（2002年至2006年）中 高级领导团队共同招募100多名癌症调查员和临床医生， 将NCI的资金增加74％，增加应计为治疗研究者发起的临床试验并增加 在这段时间内，在患者量中增加了42％。作为以癌症为中心的基本，翻译的数量 RPCI的临床和人口调查人员已经成长，四个新的共享资源已经存在 建立以支持会员资格的需求，现在还有三个正在开发中。预计 当前的高级领导团队将通过发展和执行长期来继续这项成功的轨迹 研究所的愿景和战略规划。